ClinicalTrials.govpublic full text
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
epidermolysis bullosa, amicus therapeutics, scioderm, inc., simplex, recessive dystrophic, junctional non-herlitz, sd-101 6%, sd-101-6.0, allantoin 6%, zorblisa, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 994758
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.